

BREZTRI™ AEROSPHERE®

PRODUCT MONOGRAPH





PRODUCT MONOGRAPH

INCLUDING PATIENT MEDICATION INFORMATION

BREZTRI™ AEROSPHERE®

budesonide / glycopyrronium / formoterol fumarate dihydrate pressurized inhalation suspension

Pressurized inhalation suspension, 182 mcg budesonide / 8.2 mcg glycopyrronium (as bromide) / 5.8 mcg formoterol fumarate dihydrate per metered actuation, inhalation use

Inhaled Corticosteroid (ICS) and Inhaled Bronchodilators (Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting Beta₂-Adrenergic Agonist (LABA)) Combination

AstraZeneca Canada Inc. 1004 Middlegate Road Mississauga, Ontario L4Y 1M4 www.astrazeneca.ca

Submission Control Number: 242357

Date of Initial Authorization: July 15, 2021

Date of Revision: September 30, 2021

BREZTRI™ is a trademark of, and AEROSPHERE® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, all used under license by AstraZeneca Canada Inc.



RECENT MAJOR LABEL CHANGES

Not applicable.

TABLE OF CONTENTS

	CENT MAJOR LABEL CHANGES	
TAB	BLE OF CONTENTS	
PAR	RT I: HEALTH PROFESSIONAL INFORMATION	4
1	INDICATIONS	
	1.1 Pediatrics	
	1.2 Geriatrics	4
2	CONTRAINDICATIONS	2
4	DOSAGE AND ADMINISTRATION	
	4.1 Dosing Considerations	4
	4.2 Recommended Dose and Dosage Adjustment	
	4.4 Administration	
	4.5 Missed Dose	5
5	OVERDOSAGE	5
6	DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	€
7	WARNINGS AND PRECAUTIONS	7
	7.1 Special Populations	14
	7.1.1 Pregnant Women	
	7.1.2 Breast-feeding	
	7.1.3 Pediatrics	
	7.1.4 Geriatrics	
8	ADVERSE REACTIONS	
	8.1 Adverse Reaction Overview	
	8.2 Clinical Trial Adverse Reactions	
	8.4 Post-Market Adverse Reactions	
9	DRUG INTERACTIONS	
3	9.2 Drug-Interactions Overview	
	9.4 Drug-Drug Interactions	
	9.5 Drug-Food Interactions	
	9.6 Drug-Herb Interactions	
	9.7 Drug-Laboratory Test Interactions	21
10	CLINICAL PHARMACOLOGY	21
	10.1 Mechanism of Action	
	10.2 Pharmacodynamics	
	10.3 Pharmacokinetics	
11	STORAGE, STABILITY AND DISPOSAL	26
12	SPECIAL HANDLING INSTRUCTIONS	26



PAR	T II: SCIENTIFIC INFORMATION	27
13	PHARMACEUTICAL INFORMATION	27
14	CLINICAL TRIALS	
	14.1 Clinical Trials by Indication	28
15	MICROBIOLOGY	34
16	NON-CLINICAL TOXICOLOGY	34
17	SUPPORTING PRODUCT MONOGRAPHS	35
PAT	IENT MEDICATION INFORMATION	37



PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

BREZTRI™ AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate dihydrate) is a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta₂-adrenergic agonist (LABA), indicated for the long-term maintenance treatment to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and treat airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA.

BREZTRI AEROSPHERE is **not** indicated for the treatment of acute episodes of bronchospasm (see 7 WARNINGS AND PRECAUTIONS, General).

BREZTRI AEROSPHERE is **not** indicated for the treatment of asthma.

1.1 Pediatrics

Pediatrics (< 18 years of age): The safety and efficacy of BREZTRI AEROSPHERE in pediatric patients under 18 years of age have not been established; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics (≥ 65 years of age): No dosage adjustment is required in patients 65 years of age and older.

2 CONTRAINDICATIONS

BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate dihydrate) is contraindicated in patients who are hypersensitive to this drug or to any ingredient(s) in the formulation, including any non-medicinal ingredient(s), or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

Counselling by doctors on smoking cessation should be the first step in treating patients with COPD who smoke, independent of the clinical presentation i.e., chronic bronchitis (with or without airflow limitation) or emphysema. Cessation of smoking produces dramatic symptomatic benefits and has been shown to confer a survival advantage.

As with other inhaled drugs containing beta₂-adrenergic agents, BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate dihydrate) should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA or LAMA, as an overdose may result.

When beginning treatment with BREZTRI AEROSPHERE, patients who have been taking rapid onset, short duration, inhaled beta₂-agonists on a regular basis should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief if they



develop acute respiratory symptoms while taking BREZTRI AEROSPHERE.

BREZTRI AEROSPHERE should not be used to treat acute symptoms of COPD. Patients should be prescribed a rapid onset, short duration inhaled bronchodilator to relieve the acute symptoms such as shortness of breath and advised to have this available for use at all times.

Patients should be made aware that for optimum benefit, BREZTRI AEROSPHERE must be used regularly, even when asymptomatic.

4.2 Recommended Dose and Dosage Adjustment

The recommended and maximum dose of BREZTRI AEROSPHERE is 364 mcg budesonide / 16.4 mcg glycopyrronium (as bromide) / 11.6 mcg formoterol fumarate dihydrate twice daily, administered as 2 inhalations in the morning and 2 inhalations in the evening.

Pediatrics (< 18 years of age): BREZTRI AEROSPHERE should not be used in patients under 18 years of age.

Geriatrics (≥ **65 years of age**): No dosage adjustment is required in patients 65 years of age and older.

Renal Impairment: No dosage adjustment is necessary for patients with renal impairment. However, because glycopyrronium is primarily eliminated via renal metabolism, for patients with severe renal impairment (creatine clearance of ≤30 mL/min) or end-stage renal disease requiring dialysis, BREZTRI AEROSPHERE should only be used if the expected benefit outweighs the potential risk and patients should be closely monitored.

Hepatic Impairment: No dosage adjustment is necessary for patients with hepatic impairment. However because both budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver impairment, and patients with hepatic disease should be closely monitored.

4.4 Administration

BREZTRI AEROSPHERE is for oral inhalation only.

BREZTRI AEROSPHERE should be administered as 2 inhalations twice daily, in the morning and in the evening.

To ensure proper administration of BREZTRI AEROSPHERE patients should be instructed how to administer the product correctly and advised to read the instructions for use carefully (see PATIENT MEDICATION INFORMATION, Instructions for Use).

4.5 Missed Dose

If a dose is missed, it should be taken as soon as possible, and the next dose should be taken at the usual time. A double dose should not be taken to make up for a forgotten dose.

5 OVERDOSAGE

There is limited evidence on the management of overdose with BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate dihydrate). An overdose of BREZTRI



AEROSPHERE may lead to exaggerated anticholinergic and/or β_2 -adrenergic signs and symptoms; the most frequent of which include blurred vision, dry mouth, nausea, muscle spasm, tremor, headache, palpitations and systolic hypertension. Acute overdosage with budesonide, even in excessive doses, is not expected to be a clinical problem. When used chronically in excessive doses, systemic glucocorticosteroid effects may appear.

BREZTRI AEROSPHERE should be discontinued in case of overdose. Supportive and symptomatic treatment should be initiated. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. Cardiac monitoring including electrocardiogram monitoring is recommended in cases of overdosage.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths and Composition

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Inhalation use	Pressurized inhalation suspension 182 mcg budesonide / 8.2 mcg glycopyrronium (as bromide) / 5.8 mcg formoterol fumarate dihydrate per metered actuation	Hydrofluoroalkane (HFA-134a) Porous particles (1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); Calcium chloride).

BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate dihydrate) is a pressurized inhalation suspension in a metered dose inhaler, comprising an internally-coated aluminum canister, sealed with a metering valve, fitted with an attached dose indicator device and fitted into a white plastic actuator body with a grey dust cap. Each inhaler is individually packaged in a foil laminate pouch containing a desiccant sachet and packed into a carton.

Each BREZTRI AEROSPHERE metered dose per actuation contains budesonide 182 micrograms, glycopyrronium bromide 10.4 micrograms, equivalent to 8.2 micrograms of glycopyrronium, and formoterol fumarate dihydrate 5.8 micrograms, equivalent to 5.5 micrograms of formoterol fumarate.

The delivered dose per actuation (the dose that leaves the mouthpiece) contains budesonide 160 micrograms, glycopyrronium bromide 9.0 micrograms, equivalent to 7.2 micrograms of glycopyrronium, and formoterol fumarate dihydrate 5.0 micrograms, equivalent to 4.8 micrograms of formoterol fumarate.

BREZTRI AEROSPHERE also contains hydrofluoroalkane (HFA-134a) and porous particles (comprised of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and calcium chloride) that form a co-suspension with the drug crystals.

BREZTRI AEROSPHERE is available in a carton containing 1 inhaler with either 56 or 120 actuations.



7 WARNINGS AND PRECAUTIONS

General

Not for use in asthma

The safety and efficacy of BREZTRI AEROSPHERE in patients with asthma have not been evaluated.

BREZTRI AEROSPHERE is not indicated for the treatment of asthma.

Serious Asthma-Related Events – Hospitalizations, Intubations, Death

Use of long-acting beta₂-agonists (LABA) as monotherapy (without inhaled corticosteroids [ICS]) for asthma is associated with an increased risk of asthma-related death (see 7 WARNINGS AND PRECAUTIONS, General, Salmeterol Multicenter Asthma Research Trial). Available data from controlled clinical trials also suggest that the use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone (see 7 WARNINGS AND PRECAUTIONS, General, Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta₂-adrenergic Agonist Combination Products).

Available data do not suggest an increased risk of death with use of LABA in patients with COPD.

Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta₂-adrenergic Agonist Combination Products

Four (4) large, 26-week, randomized, double-blind, active-controlled clinical safety trials were conducted to evaluate the risk of serious asthma-related events when LABA were used in fixed-dose combination with ICS compared with ICS alone in subjects with asthma. Three (3) trials included adult and adolescent subjects aged 12 years and older: 1 trial compared budesonide/formoterol with budesonide, 1 trial compared fluticasone propionate/salmeterol with fluticasone propionate, and 1 trial compared mometasone furoate/formoterol with mometasone furoate. The fourth trial included pediatric subjects aged 4 to 11 years and compared fluticasone propionate/salmeterol with fluticasone propionate. The primary safety endpoint for all 4 trials was serious asthma-related events (hospitalizations, intubations, death). A single, blinded, independent, joint adjudication committee determined whether events were asthma related.

The 3 adult and adolescent trials were designed to rule out a 2.0-fold increase in relative risk for ICS/LABA compared with ICS, and the pediatric trial was designed to rule out a 2.7-fold increase in this relative risk. Each individual trial met its pre-specified objective and demonstrated non-inferiority of ICS/LABA to ICS alone. A meta-analysis of the 3 adult and adolescent trials did not show a significant increase in risk of a serious asthma-related event with ICS/LABA fixed-dose combination compared with ICS alone (Table 2). These trials were not designed to rule out all risk for serious asthma-related events with ICS/LABA compared with ICS.



Table 2 – Meta-analysis of serious asthma-related events in subjects with asthma aged 12 years and older

aged 12 years and older			
	ICS/LABA (n=17,537) ^a	ICS (n=17,552) ^a	ICS/LABA vs. ICS Hazard Ratio (95% CI) ^b
Serious asthma-related event ^c	116	105	1.10 (0.85, 1.44)
Asthma-related death	2	0	
Asthma-related intubation (endotracheal)	1	2	
Asthma-related hospitalization (≥24-hour stay)	115	105	

ICS = Inhaled corticosteroid; LABA = Long-acting beta₂-adrenergic agonist.

Salmeterol Multicenter Asthma Research Trial

A 28-week, placebo-controlled, U.S. trial that compared the safety of salmeterol with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in subjects receiving salmeterol (13/13,176 in subjects treated with salmeterol versus 3/13,179 in subjects treated with placebo; relative risk: 4.37 [95% CI: 1.25, 15.34]). Use of background ICS was not required in the Salmeterol Multicenter Asthma Research Trial. The increased risk of asthma-related death is considered a class effect of LABA monotherapy.

Deterioration of disease

BREZTRI AEROSPHERE should not be initiated in patients with acutely deteriorating COPD which may be a life-threatening condition. The use of BREZTRI AEROSPHERE in this setting has not been studied and is not considered appropriate.

COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If BREZTRI AEROSPHERE no longer controls symptoms of bronchoconstriction, the patient's inhaled, short-acting bronchodilator becomes less effective or the patient needs more inhalation of a short-acting bronchodilator than usual, these may be markers of deterioration of disease. In this setting, a re-evaluation of the patient and the treatment regimen should be undertaken at once. Consideration should be given to the need for increased therapy such as a course of oral corticosteroids or antibiotic treatment if an infection is present.

Exacerbations may occur during treatment with BREZTRI AEROSPHERE. Patients should be advised to continue treatment and seek medical advice if symptoms remain uncontrolled or worsen after initiation of therapy with BREZTRI AEROSPHERE.

Patients should not stop therapy with BREZTRI AEROSPHERE without physician supervision since symptoms may recur after discontinuation.

^a Randomized subjects who had taken at least 1 dose of study drug. Planned treatment used for analysis.

^b Estimated using a Cox proportional hazards model for time to first event with baseline hazards stratified by each of the 3 trials.

^c Number of subjects with an event that occurred within 6 months after the first use of study drug or 7 days after the last date of study drug, whichever date was later. Subjects may have had one or more events, but only the first event was counted for analysis. A single, blinded, independent, joint adjudication committee determined whether events were asthma related.



Not for acute use

BREZTRI AEROSPHERE should not be used for the relief of acute symptoms of COPD (i.e., as rescue therapy for the treatment of acute episodes of bronchospasm).

Patients should be prescribed a rapid onset, short duration inhaled bronchodilator to relieve acute symptoms such as shortness of breath, and advised to have this available for use at all times.

When beginning treatment with BREZTRI AEROSPHERE, patients who have been taking a rapid onset, short duration, inhaled bronchodilator on a regular basis should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief if they develop acute symptoms while taking BREZTRI AEROSPHERE.

Excessive use and use with other LABA and LAMA products

BREZTRI AEROSPHERE should not be used more often or at higher doses than recommended.

BREZTRI AEROSPHERE should not be administered concomitantly with other medicines containing a long-acting beta₂-adrenergic agonist (e.g., salmeterol, formoterol fumarate, indacaterol, olodaterol), or a long-acting muscarinic antagonist (e.g., tiotropium, glycopyrronium, aclidinium, umeclidinium) for any reason, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

Anticholinergic activity

Due to its anticholinergic activity, BREZTRI AEROSPHERE should be used with caution in patients with symptomatic prostatic hyperplasia, urinary retention (see 7 WARNINGS AND PRECAUTIONS, Renal) or narrow-angle glaucoma (see 7 WARNINGS AND PRECAUTIONS, Ophthalmologic).

Cardiovascular

Cardiovascular effects, such as cardiac arrhythmias, e.g., atrial fibrillation and tachycardia, may be seen after the administration of sympathomimetic agents and muscarinic receptor antagonists, including BREZTRI AEROSPHERE. In case such effects occur, treatment may need to be discontinued.

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Cardiovascular effects such as tachycardia, arrhythmia, palpitations, myocardial ischemia, angina pectoris, hypertension or hypotension have been associated with use of beta-adrenergic agonists. In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. Like all products containing sympathomimetic agents, BREZTRI AEROSPHERE should therefore be used with caution in patients with unstable or life-threatening cardiovascular disease, especially coronary insufficiency, cardiac arrhythmias (including tachyarrhythmias), or hypertension.

Heart rate

Like other beta₂-agonists, formoterol fumarate can produce clinically significant cardiovascular effects in some patients as measured by an increase in pulse rate, systolic or diastolic blood pressure or cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles. If such effects occur, BREZTRI AEROSPHERE may need to be discontinued.



QT Interval

As with other beta₂-agonists, caution is recommended if BREZTRI AEROSPHERE is administered to patients with a known history of QTc prolongation, risk factors for torsade de pointes (e.g., hypokalemia), or patients who are taking medications known to prolong the QTc interval (see 9 DRUG INTERACTIONS9.4 Drug-Drug Interactions, Drugs known to prolong the QTc interval; and 10 CLINICAL PHARMACOLOGY).

Driving and Operating Machinery

No studies on the effects on the ability to drive and use machines have been performed. Based on the pharmacological profile (see 10 CLINICAL PHARMACOLOGY), BREZTRI AEROSPHERE is expected to have no or negligible influence on the ability to drive and use machines. The occurrence of headache or nausea may influence the ability to drive or to use machinery.

Ear/Nose/Throat

BREZTRI AEROSPHERE contains budesonide, an ICS. Therapeutic dosages of budesonide may cause the appearance of *Candida albicans* (thrush) in the mouth and throat. Advise the patient to rinse his/her mouth with water without swallowing following inhalation to help reduce the risk of oropharyngeal candidiasis.

The development of pharyngeal and laryngeal candidiasis is a cause for concern because the extent of its penetration into the respiratory tract is unknown. Symptomatic candidiasis can be treated with topical anti-fungal therapy while continuing to use BREZTRI AEROSPHERE.

Endocrine and Metabolism

Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods.

These effects are much less likely to occur with inhaled corticosteroid treatments than with oral corticosteroids. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, cataract and glaucoma. Potential effects on bone density should be considered particularly in patients on high doses for prolonged periods that have co-existing risk factors for osteoporosis. Long-term studies with inhaled budesonide in adults at daily doses of 800 micrograms (metered dose) have not shown any significant effects on bone mineral density (see 7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism, Reduction in Bone Mineral Density and 7 WARNINGS AND PRECAUTIONS, Ophthalmologic).

Hypercorticism and Adrenal Suppression

Budesonide, a component of BREZTRI AEROSPHERE, will often help control COPD symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Inhaled budesonide is absorbed into the circulation and can be systemically active. Effects of budesonide on the HPA axis are not observed with the therapeutic doses of budesonide in BREZTRI AEROSPHERE. Exceeding the recommended dosage or coadministration with a strong cytochrome P450 3A4 (CYP3A4) inhibitor may result in HPA dysfunction. The beneficial effects of BREZTRI AEROSPHERE in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded.

Because of the possibility of systemic absorption of ICS, patients treated with BREZTRI AEROSPHERE should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.



It is possible that systemic corticosteroid effects, such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects. If such effects occur, when appropriate, therapy should be initiated.

Systemic Steroid Replacement by Inhaled Steroid

Particular care is needed for patients who have been transferred from systemically active corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients during and after transfer from systemic corticosteroids to less systemically available ICS. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function.

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although BREZTRI AEROSPHERE may provide control of COPD symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticoid systemically and does not provide the mineralocorticoid activity that is necessary for coping with these emergencies.

During periods of stress, or a severe COPD exacerbation, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their healthcare professional for further instruction. These patients should also be instructed to carry a warning card indicating that they may need supplementary systemic corticosteroids during periods of stress, or a severe COPD exacerbation.

Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to BREZTRI AEROSPHERE. Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with BREZTRI AEROSPHERE. Lung function (forced expiratory volume in 1 second [FEV₁] or morning peak expiratory flow [PEF]), beta-agonist use, and COPD symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to BREZTRI AEROSPHERE may unmask allergic conditions previously suppressed by the systemic corticosteroid therapy (e.g., rhinitis, conjunctivitis, eczema, arthritis, eosinophilic conditions). During withdrawal from oral corticosteroids, some patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression) despite maintenance or even improvement of respiratory function.

Reduction in Bone Mineral Density

Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing ICS. The clinical significance of small changes in BMD with regard to long-term consequences such as fracture is unknown. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. If significant reductions in BMD are seen and



BREZTRI AEROSPHERE is still considered medically important for that patient's COPD therapy, use of therapy to treat or prevent osteoporosis should be strongly considered. See 10 CLINICAL PHARMACOLOGY, 10.2 Pharmacodynamics, Bone Density and Ocular Effects.

Hypokalemia and hyperglycemia

Beta-adrenergic agonist medications may produce significant hypokalemia in some patients, which has the potential to produce adverse cardiovascular effects. Metabolic effects of hyperglycemia and hypokalemia may be observed with high doses of β_2 adrenergic agonists. The decrease in serum potassium is usually transient, not requiring supplementation. BREZTRI AEROSPHERE should be used with caution in patients predisposed to low levels of serum potassium. In patients with severe COPD, hypokalemia may be potentiated by hypoxia and concomitant treatment (see 9 DRUG INTERACTIONS), which may increase the susceptibility to cardiac arrhythmias.

Inhalation of high doses of beta₂-adrenergic agonists may produce increases in plasma glucose. Upon initiation of treatment with BREZTRI AEROSPHERE, plasma glucose should be monitored more closely in diabetic patients. BREZTRI AEROSPHERE has not been studied in patients whose diabetes mellitus is not controlled.

In one clinical trial of 24 weeks that included a 28-week safety extension study, and in one 52-week study evaluating BREZTRI AEROSPHERE in subjects with COPD, there was no evidence of a treatment effect on potassium.

Co-existing conditions

BREZTRI AEROSPHERE, like all medications containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Doses of the rapid onset, short-duration, beta₂-adrenoceptor agonist salbutamol, when administered intravenously, have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis.

Hematologic

Eosinophilic conditions

In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions, with some patients presenting with clinical features of vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA) (formerly Churg-Strauss syndrome), a condition that is often treated with systemic corticosteroid therapy. These events usually, but not always, have been associated with the reduction and/or withdrawal of oral corticosteroid therapy following the introduction of inhaled corticosteroid. Physicians should be alerted to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal relationship between inhaled corticosteroid and these underlying conditions has not been established.

Hepatic/Biliary/Pancreatic

As budesonide and formoterol are primarily eliminated via hepatic metabolism an increased exposure can be expected in patients with severe hepatic impairment.

In patients with severe hepatic impairment, BREZTRI AEROSPHERE should be used only if the expected benefit outweighs the potential risk (see 10 CLINICAL PHARMACOLOGY). Patients with hepatic disease should be closely monitored.

Immune

Patients who are using drugs that suppress the immune system are more susceptible to



infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible patients using corticosteroids. In such patients who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If a patient is exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If a patient is exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. If chickenpox develops, treatment with antiviral agents may be considered.

As with all medications containing a corticosteroid, BREZTRI AEROSPHERE should be administered with caution, and only if necessary, in patients with active or quiescent tuberculosis infections of the respiratory tract; chronic or untreated infections such as systemic fungal, bacterial, viral, or parasitic; or ocular herpes simplex.

Monitoring and Laboratory Tests

Potentially serious hypokalemia has been observed with other beta-agonist therapies, which may increase susceptibility to cardiac arrhythmias. It is therefore recommended that serum potassium levels be monitored in patients predisposed to low levels of serum potassium.

Due to the hyperglycemic effect observed with other beta-agonists, additional blood glucose monitoring is recommended in diabetic patients.

For patients at risk, monitoring of bone and ocular effects (cataract and glaucoma) should also be considered in patients receiving maintenance therapy with BREZTRI AEROSPHERE.

Patients with hepatic impairment should be monitored for corticosteroid effects due to potentially increased systemic exposure of budesonide.

Ophthalmologic

Glaucoma and increased intraocular pressure have been reported in patients with COPD following the long-term administration of inhaled corticosteroids or with use of inhaled anticholinergics. Cataracts have also been reported in patients with COPD following the long-term administration of inhaled corticosteroids.

BREZTRI AEROSPHERE, like other antimuscarinic-containing products, should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should also be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a healthcare provider immediately if any of these signs or symptoms develops.

Close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, narrow- or open-angle glaucoma, and cataracts.

See 10 CLINICAL PHARMACOLOGY, 10.2 Pharmacodynamics, Bone Density and Ocular Effects.

Renal

BREZTRI AEROSPHERE, like other antimuscarinic-containing products, should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in



patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a healthcare provider immediately if any of these signs or symptoms develops.

Formal pharmacokinetic studies using BREZTRI AEROSPHERE have not been conducted in patients with renal impairment. As glycopyrronium is predominantly renally excreted, patients with severe renal impairment (creatinine clearance of <30 mL/min) should be treated with BREZTRI AEROSPHERE only if the expected benefit outweighs the potential risk. These patients should be closely monitored for potential adverse drug reactions.

Reproductive Health

Fertility

Studies in rats have shown slight reductions in fertility only at dose levels higher than the maximum human exposure to formoterol (see 16 NON-CLINICAL TOXICOLOGY). Budesonide and glycopyrronium individually, did not cause any adverse effects on fertility in rats. It is unlikely that BREZTRI AEROSPHERE administered at the recommended dose will affect fertility in humans.

Respiratory

Paradoxical bronchospasm

As with other inhaled medicines, administration of BREZTRI AEROSPHERE may cause paradoxical bronchospasm. If this occurs, treatment with BREZTRI AEROSPHERE should be stopped and other treatments considered.

Pneumonia

In line with the known class effect of inhaled corticosteroids, pneumonia events (including pneumonias resulting in hospitalization) were observed in patients with COPD receiving BREZTRI AEROSPHERE. In some instances, fatal events of pneumonia have been reported with use of inhaled corticosteroid budesonide-containing drugs, including BREZTRI AEROSPHERE (see 8 ADVERSE REACTIONS). Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections can overlap with the symptoms of COPD exacerbations. Risk factors for pneumonia in patients with COPD receiving inhaled corticosteroid-containing drugs include current smokers, patients with a history of prior pneumonia, patients with low body mass index and patients with severe COPD. These factors should be considered when BREZTRI AEROSPHERE is prescribed, and treatment should be re-evaluated if pneumonia occurs.

Sensitivity/Resistance

As with all medications, immediate hypersensitivity reactions may occur after administration of BREZTRI AEROSPHERE. If signs suggesting allergic reactions (in particular, difficulties in breathing or swallowing, swelling of tongue, lips and face, urticaria or skin rash) occur, therapy with BREZTRI AEROSPHERE should be stopped at once and alternative treatments should be considered. The patient should NOT be re-challenged with BREZTRI AEROSPHERE if this is identified as the cause of the hypersensitivity reaction (see 2 CONTRAINDICATIONS).

7.1 Special Populations

7.1.1 Pregnant Women

There are no adequate data on the use of BREZTRI AEROSPHERE in pregnant women. Data on the use of inhaled budesonide in more than 2500 exposed pregnancies indicate no increased teratogenic risk associated with budesonide. Single-dose studies in humans found that



very small amounts of glycopyrronium passed the placental barrier. There are no adequate data from use of formoterol or glycopyrronium in pregnant women.

No animal reproductive toxicology studies have been conducted with BREZTRI AEROSPHERE. Budesonide has been shown to induce embryofoetal toxicity in rats and rabbits, a class effect of glucocorticoids. At very high doses/systemic exposure levels, formoterol caused implantation losses as well as decreases in birth weight and early postnatal survival, whereas glycopyrrolate had no significant effects on reproduction (see 16 NON-CLINICAL TOXICOLOGY).

BREZTRI AEROSPHERE should only be used during pregnancy if the expected benefits outweigh the potential risks.

7.1.2 Breast-feeding

A clinical pharmacology study has shown that inhaled budesonide is excreted in breast milk. However, budesonide was not detected in nursing infant blood samples. Based on pharmacokinetic parameters, the plasma concentration in the child is estimated to be less than 0.17% of the mother's plasma concentration. Consequently, no effects due to budesonide are anticipated in breast-fed children whose mothers are receiving therapeutic doses of BREZTRI AEROSPHERE. It is not known whether glycopyrronium or formoterol are excreted in human milk. Evidence of transfer of glycopyrronium and formoterol into maternal milk in rats has been reported.

Administration of BREZTRI AEROSPHERE to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.

7.1.3 Pediatrics

BREZTRI AEROSPHERE is not indicated in the pediatric population as the safety and efficacy of BREZTRI AEROSPHERE has not been evaluated in patients less than 18 years of age.

7.1.4 Geriatrics

No dosage adjustment is required in patients 65 years of age and older, however greater sensitivity in some older individuals cannot be ruled out.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The overall safety profile of BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate dihydrate) was generally consistent with the known pharmacologic class effects of ICSs, LAMAs and/or LABAs.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.



As BREZTRI AEROSPHERE contains budesonide, glycopyrronium and formoterol fumarate dihydrate, the type and severity of adverse reactions associated with each of the components may be expected with BREZTRI AEROSPHERE.

The safety evaluation of the pivotal program for BREZTRI AEROSPHERE 182/8.2/5.8 mcg per metered actuation included 2144 subjects with COPD in one 52-week clinical trial (PT010005), and 639 subjects with COPD in one 24-week clinical trial (PT010006).

Adverse drug reactions that occurred at a frequency of ≥1% are listed by MedDRA system organ class.

Table 3 Adverse drug reactions occurring in ≥1% of subjects with BREZTRI AEROSPHERE for the 52-week exacerbation trial (PT010005)

	BREZTRI AEROSPHERE ¹ n = 2144 N (%)	GFF MDI ¹ n = 2125 N (%)	BFF MDI ¹ n = 2136 N (%)					
Gastrointestinal disord	Gastrointestinal disorders							
Nausea	28 (1.3)	21 (1.0)	24 (1.1)					
General disorders and	administration site cor	nditions						
Chest pain	21 (1.0)	14 (0.7)	22 (1.0)					
Infections and infestat	ions							
Pneumonia	98 (4.6)	61 (2.9)	107 (5.0)					
Oral candidiasis	65 (3.0)	24 (1.1)	57 (2.7)					
Metabolism and nutrit	ion disorders		_					
Hyperglycemia	26 (1.2)	20 (0.9)	21 (1.0)					
Musculoskeletal and c	onnective tissue disord	lers	,					
Muscle spasms	60 (2.8)	19 (0.9)	53 (2.5)					
Nervous system disor	ders							
Headache	57 (2.7)	60 (2.8)	68 (3.2)					
Psychiatric disorders								
Anxiety	30 (1.4)	24 (1.1)	28 (1.3)					
Insomnia	30 (1.4)	23 (1.1)	11 (0.5)					
Renal and urinary disc	orders							
Urinary tract infection	58 (2.7)	60 (2.8)	41 (1.9)					
Respiratory, thoracic and mediastinal								
Cough	58 (2.7)	50 (2.4)	51 (2.4)					
Dysphonia	37 (1.7)	7 (0.3)	31 (1.5)					
Skin and subcutaneou	s tissue disorders		T					
Bruising	22 (1.0)	14 (0.7)	16 (0.7)					



Abbreviations: GFF = glycopyrronium/formoterol fumarate dihydrate; BFF = budesonide and formoterol fumarate dihydrate; MDI = metered dose inhaler.

¹Administered orally as two inhalations of BREZTRI AEROSPHERE 182/8.2/5.8 mcg, GFF MDI 8.2/5.8 mcg, BFF MDI 182/5.8 mcg, twice daily.

Table 4 Adverse drug reactions occurring in ≥1% of subjects with BREZTRI AEROSPHERE for the 24-week lung function trial (PT010006)

	BREZTRI AEROSPHERE ¹ n = 639 N (%)	GFF MDI ¹ n = 625 N (%)	BFF MDI ¹ n = 314 N (%)			
Gastrointestinal disorders						
Nausea	7 (1.1)	3 (0.5)	4 (1.3)			
Infections and infestations						
Pneumonia	12 (1.9)	10 (1.6)	6 (1.9)			
Oral candidiasis	10 (1.6)	5 (0.8)	5 (1.6)			
Musculoskeletal and conne	ctive tissue disorders					
Muscle spasms	21 (3.3)	8 (1.3)	17 (5.4)			
Renal and urinary disorders	3					
Urinary tract infection	12 (1.9)	10 (1.6)	4 (1.3)			
Respiratory, thoracic and mediastinal disorders						
Dysphonia	20 (3.1)	5 (0.8)	15 (4.8)			
Cough	11 (1.7)	9 (1.4)	3 (1.0)			

Abbreviations: GFF = glycopyrronium/formoterol fumarate dihydrate; BFF = budesonide and formoterol fumarate dihydrate; MDI = metered dose inhaler.

Pneumonia

In PT010005, a 52-week trial of subjects with moderate to very severe COPD (N = 8,529) and a history of 1 or more moderate or severe COPD exacerbations in the year prior, the overall incidence of confirmed pneumonia was 4.2% for BREZTRI AEROSPHERE 364/16.4/11.6 mcg (n = 2144), 3.5% for budesonide, glycopyrronium and formoterol fumarate [BGF MDI 182/16.4/11.6 mcg] (n = 2124), 2.3% for GFF MDI 16.4/11.6 mcg (n = 2125) and 4.5% for BFF MDI 364/11.6 mcg (n = 2136). Fatal cases of pneumonia occurred in 2 subjects receiving BGF MDI 182/16.4/11.6 mcg, 3 subjects receiving GFF MDI 16.4/11.6 mcg, and no subjects receiving BREZTRI AEROSPHERE 364/16.4/11.6 mcg.

In PT010006, a 24-week trial of subjects with moderate to very severe COPD (N = 1,896), the incidence of confirmed pneumonia was low and similar across treatment groups and was 1.9% for BREZTRI AEROSPHERE 364/16.4/11.6 mcg (n = 639), 1.6% for glycopyrronium and formoterol fumarate [GFF MDI 16.4/11.6 mcg] (n = 625) and 1.9% for budesonide and formoterol

¹Administered orally as two inhalations of BREZTRI AEROSPHERE 182/8.2/5.8 mcg, GFF MDI 8.2/5.8 mcg or BFF MDI 182/5.8 mcg twice daily.



fumarate [BFF MDI 364/11.6 mcg] (n = 320). There were no fatal cases of pneumonia with BREZTRI AEROSPHERE in the study.

8.3 Less Common Clinical Trial Adverse Reactions

Other less common adverse reactions that occurred with a frequency of <1.0% in patients receiving BREZTRI AEROSPHERE are listed below.

Cardiovascular disorders: angina pectoris, tachycardia, cardiac arrhythmias (atrial fibrillation, supraventricular tachycardia and extrasystoles), palpitations

Endocrine disorders: signs or symptoms of systemic glucocorticosteroid effects, e.g.

hypofunctions of the adrenal gland Gastrointestinal disorders: dry mouth Immune system disorders: hypersensitivity

Psychiatric disorders: depression, agitation, restlessness, nervousness, abnormal behaviour

Nervous system disorders: tremor, dizziness Renal and urinary disorders: urinary retention

Respiratory, thoracic and mediastinal disorders: throat irritation, bronchospasm

8.4 Post-Market Adverse Reactions

No post-marketing Adverse Drug Reactions have been identified to date for BREZTRI AEROSPHERE.

9 DRUG INTERACTIONS

9.2 Drug-Interactions Overview

No formal drug interaction studies have been performed with BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate dihydrate). Information on BREZTRI AEROSPHERE is based on the potential for interactions for each of its components.

Co-administration of BREZTRI AEROSPHERE with other anticholinergic and/or long-acting β_2 -adrenergic agonist containing medicinal products has not been studied and is not recommended.

9.4 Drug-Drug Interactions

Metabolic interactions

The metabolism of budesonide is primarily mediated by CYP3A4. Co-treatment with strong CYP3A inhibitors, e.g. itraconazole, ketoconazole, HIV protease inhibitors and cobicistat-containing products, are expected to increase the risk of systemic side effects (see 7 WARNINGS AND PRECAUTIONS and 10 CLINICAL PHARMACOLOGY). If a patient requires long-term concomitant treatment with BREZTRI AEROSPHERE and a strong CYP3A4 inhibitor, the benefit should be weighed against the increased risk of systemic corticosteroid side effects, patients should be monitored for corticosteroid side effects.

Since glycopyrronium is eliminated mainly by the renal route, drug interactions could potentially occur with medicinal products affecting renal excretion mechanisms. *In-vitro* glycopyrronium is a substrate for the renal transporters OCT2 and MATE1/2K. The effect of cimetidine, a probe inhibitor of OCT2 and MATE1, on inhaled glycopyrronium disposition showed an increase in its total systemic exposure (AUC_{0-t}) by 22% and a decrease in renal clearance by 23% due to co-



administration of cimetidine. No clinically relevant drug interaction is expected in patients with normal renal function and also in patients with mild to moderate renal impairment.

Formoterol does not inhibit the CYP450 enzymes at therapeutically relevant concentrations (see 10 CLINICAL PHARMACOLOGY). Budesonide and glycopyrronium do not inhibit or induce CYP450 enzymes at therapeutically relevant concentrations (see 10 CLINICAL PHARMACOLOGY).

Sympathomimetic Agents

Concomitant administration of other sympathomimetic agents (alone or as part of combination therapy) may potentiate the undesirable effects of BREZTRI AEROSPHERE (see 7 WARNINGS AND PRECAUTIONS).

Treatments leading to hypokalemia

Concomitant treatment with methylxanthine derivatives, oral corticosteroids (e.g., prednisone), or non-potassium-sparing diuretics may potentiate the possible initial hypokalemic effect of beta₂-adrenergic agonists, therefore caution is advised in their concomitant use (see 7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism, Hypokalemia and hyperglycemia).

β-adrenergic blockers

Beta-adrenergic blockers (including eye drops) can weaken or inhibit the effect of formoterol. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

Drugs Known to Prolong the QTc Interval

BREZTRI AEROSPHERE, as with other beta₂-agonists, should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants or other drugs known to prolong the QTc interval, as any effect of these on the QT interval may be potentiated. Drugs that are known to prolong the QTc interval may be associated with an increased risk of ventricular arrhythmias (see 7 WARNINGS AND PRECAUTIONS, and 10 CLINICAL PHARMACOLOGY).



Table 5 – Established or Potential Drug-Drug Interactions

Drug Type	Source of Evidence	Effect	Clinical comment
CYP3A4 inhibitors	СТ	Expected to increase the risk of systemic side effects	Caution should be exercised during long-term treatment with a strong CYP3A4 inhibitor (e.g. itraconazole, ketoconazole, HIV protease inhibitors and cobicistat-containing products)
Sympathomimetic Agents	T	Potential pharmacodynamic interaction (additive pharmacologic and adverse effects)	Caution is recommended during concomitant use with long acting sympathomimetic agents administered by any route
Methylxanthine derivatives, oral corticosteroids (e.g., prednisone), or non- potassium sparing diuretics	Т	Potential pharmacodynamic interaction (increased risk of hypokalemia)	Caution is recommended during concomitant therapy
Beta-adrenergic blockers (including ophthalmic agents)	Т	Beta-adrenergic blockers may weaken or antagonize the effect of beta ₂ - adrenergic agonists resulting in severe bronchospasm	If concomitant therapy is required, cardioselective beta-adrenergic blockers could be considered, although they should be administered with caution
Drugs known to prolong QTc interval Monoamine Oxidase Inhibitors Tricyclic Antidepressants	Т	Potential pharmacodynamics interaction (prolongation of the QTc interval and increased risk of ventricular arrhythmias)	Caution is recommended during concomitant therapy
Anticholinergics	Т	Potential for an additive interaction with concomitantly used anticholinergic medications	Avoid co- administration with other anticholinergic- containing drugs administered by any route

Legend: CT = Clinical Trial; T = Theoretical



9.5 Drug-Food Interactions

No formal drug-food interaction studies have been conducted. No clinically relevant effect of food would be expected and therefore a food interaction study was not conducted.

9.6 Drug-Herb Interactions

No formal drug-herb interaction studies have been conducted.

9.7 Drug-Laboratory Test Interactions

No formal drug-laboratory test interaction studies have been conducted.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate dihydrate) contains budesonide, a glucocorticosteroid, and two bronchodilators: glycopyrronium, a long-acting muscarinic antagonist (anticholinergic) and formoterol, a long-acting β_2 -adrenergic agonist. The combination of these substances with different mechanisms of action results in increased efficacy compared to use with any of the dual component therapies. The respective mechanism of action of each drug is discussed below.

Budesonide, when inhaled, has a rapid (within hours) and dose dependent anti-inflammatory action in the airways, resulting in reduced symptoms and fewer COPD exacerbations. Inhaled budesonide has less severe adverse effects than systemic corticosteroids.

Glycopyrronium has a rapid onset of action and has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, bronchodilation is induced through inhibition of the M3 receptor at the smooth muscle.

Formoterol has a rapid onset of action. Bronchodilation is induced by causing direct relaxation of airway smooth muscle as a consequence of the increase in cyclic AMP through activation of adenylate cyclase.

As a consequence of the differential density of muscarinic receptors and β_2 -adrenoceptors in the central and peripheral airways of the lung, muscarinic antagonists are more effective in relaxing central airways and β_2 -adrenergic agonists are more effective in relaxing peripheral airways; relaxation of both central and peripheral airways with combination treatment may contribute to its beneficial effects on lung function.

10.2 Pharmacodynamics

Time to Onset of Action

Rapid onset of action was achieved for BREZTRI AEROSPHERE. The median time to a 100 mL or larger improvement in FEV₁ was within 5 minutes of the first dose on Day 1, with a change from baseline of 166 mL (PT010005) and 175 mL (PT010006) observed at 5 minutes post-dose for BREZTRI AEROSPHERE.

Class-Related Beta2-Adrenoceptor Systemic Effects

Class-related systemic effects that are known to occur with systemic administration of beta-



agonists include hypokalemia, hyperglycemia, and increases in blood pressure, heart rate and the QTc interval. Following inhaled administration these effects are limited by local topical administration in the lung, low clinical doses and first pass metabolism of the swallowed portion of the dose.

In PT010005, a 52-week trial of subjects with COPD, no clinically meaningful trends were observed in laboratory parameters (including potassium and glucose), vital signs (heart rate, systolic blood pressure, or diastolic blood pressure), or electrocardiogram (ECG) parameters (Calculated Fridericia-corrected QT, PR or QRS interval prolongation) over time across the treatment groups. The incidence of post-baseline newly occurring or worsening potentially clinically significant laboratory, vital sign parameters, and ECG parameters was generally low and similar across treatment groups.

Cardiovascular effects

A thorough QT study was not performed with BREZTRI AEROSPHERE as budesonide is not known to affect the QT interval. The potential for QTc interval prolongation with glycopyrronium/formoterol fumarate was assessed in a randomized double-blind, single-dose, placebo- and positive-controlled crossover trial in 69 healthy subjects. The largest mean (90% confidence interval [CI]) differences from placebo in baseline-corrected Individual-specific corrected QT (QTcI) interval for a single-dose treatment of glycopyrronium/formoterol fumarate dihydrate 16.6/11.6 mcg (therapeutic dose) and 132.8/46.4 mcg (supra-therapeutic dose), were 3.1 (90% CI [1.4, 4.7]) ms at 0.17 h and 7.6 (90% CI [6.0, 9.2]) ms at 0.33 h, respectively. No effect on the QTcI interval was observed in the glycopyrronium 132.8 mcg single component treatment arm.

A dose-dependent increase in heart rate was also observed. The largest mean (90% confidence interval) differences from placebo in baseline-corrected heart rate were 3.3 (90% CI [1.8, 4.9]) beats/min at 0.1h and 7.6 (90% CI [5.6, 9.5]) beats/min at 0.17 h with glycopyrronium/formoterol fumarate dihydrate 16.6/11.6 mcg (therapeutic dose) and 132.8/46.4 mcg (supra-therapeutic dose), respectively.

Budesonide is not known to effect cardiac rhythm. The effect of glycopyrronium and/or formoterol fumarate on cardiac rhythm in subjects with COPD was assessed using 24-hour Holter monitoring at Week 16 in Study PT010005. All treatments were administered as two inhalations twice daily. The Holter monitoring population in Study PT010005 included 180 subjects on BREZTRI AEROSPHERE 364/16.4/11.6 mcg, 160 subjects on glycopyrronium and formoterol fumarate (GFF MDI 16.4/11.6), and 183 subjects on budesonide/formoterol fumarate (BFF MDI 364/11.6 mcg). The results of this sub-study in COPD patients showed no notable differences across treatment groups for any of the Holter endpoints, including heart rate (change from baseline: 24-hour mean, daytime mean, nighttime mean, 24-hour maximum, and 24-hour minimum), ventricular arrhythmias, and supraventricular arrhythmias. No clinically meaningful effects on cardiac rhythm were observed across treatment groups, including heart rate (change from baseline: 24-hour mean, daytime mean, nighttime mean, 24-hour maximum, and 24-hour minimum), ventricular arrhythmias, and supraventricular arrhythmias.

HPA Axis Effects

Effects of BREZTRI AEROSPHERE on the HPA axis were assessed by measurement of 24-hour plasma cortisol at Baseline and Week 24 in subjects with COPD. The geometric mean ratio (Week 24/Baseline) was 0.86 for BREZTRI AEROSPHERE and 0.94 for GFF MDI 16.4 mcg/11.6 mcg, respectively.



Bone Density and Ocular Effects

Effects of BREZTRI AEROSPHERE on bone density and ocular outcomes were assessed in a subset of patients in study PT010006 who were then treated in the 28-week extension study PT010008 for a total of up to 52 weeks. In study PT010006, BREZTRI AEROSPHERE 364/16.4/11.6 mcg was non-inferior to GFF MDI 16.4/11.6 mcg for the primary bone mineral density and ocular endpoints. In patients in study PT010005 treated for up to 52 weeks, the incidence of cataracts was comparable across the budesonide-containing and non-budesonide-containing treatment groups.

10.3 Pharmacokinetics

Linear pharmacokinetics were demonstrated for budesonide (80 to 320 mcg), glycopyrronium bromide (18 to 144 mcg), and formoterol fumarate (2.4 to 38.4 mcg). Pharmacokinetic information for glycopyrrolate and formoterol fumarate is for the active moieties, glycopyrronium and formoterol, respectively. The pharmacokinetics of budesonide, glycopyrronium, and formoterol from BREZTRI AEROSPHERE are comparable to the pharmacokinetics of budesonide, glycopyrronium, and formoterol when administered as budesonide/formoterol or glycopyrronium bromide/formoterol in studies of healthy subjects (single dose) and subjects with COPD (repeated dose).

Table 6 - Summary of BREZTRI AEROSPHERE Pharmacokinetic Parameters in subjects with COPD

	C _{max} ¹ (pg/mL)	T _{max} (h)	t _{1/2} (h)	AUC ₀₋₁₂ 1 (pg·h/mL)	CL¹ (L/h)
	0	Single de	ose ³	, , ,	
Budesonide	709.3 (57.2)	0.33 (0.10, 1.03)	6.2 (24.7)	2407 (45.4)	106.8 (41.0)
Glycopyrronium	17.2 (80.7)	0.03 (0.03, 4.00)	8.5 (131.8)	42.5 (45.8)	235.5 (85.1)
Formoterol	6.4 (48.1)	0.33 (0.10, 9.97)	5.9 (40.7)	32.6 (30.3)	208.8 (33.7)
		Repeat d	ose ⁴		
Budesonide	663.2 (65.8)	0.67 (0.10, 2.00)	N/A	3005 (58.5)	N/A
Glycopyrronium	18.3 (65.4)	0.10 (0.03, 1.00)	N/A	73.9 (52.9)	N/A
Formoterol	7.4 (38.1)	0.67 (0.03, 12.00)	N/A	47.4 (30.0)	N/A

N/A = not applicable

Absorption:

Budesonide

Following inhaled administration of BREZTRI AEROSPHERE in subjects with COPD, budesonide C_{max} occurred within 20 to 40 minutes. Steady state is achieved after approximately

¹ expressed as the geometric mean (coefficient of variation)

² expressed as median values (range)

³ Assessed following a single dose administration on the first treatment day (Day 1)

⁴ Assessed following 7 days of repeat dosing



1 day of repeated dosing of BREZTRI AEROSPHERE and the extent of exposure is approximately 1.3 times higher than after the first dose.

Glycopyrronium

Following inhaled administration of BREZTRI AEROSPHERE in subjects with COPD, glycopyrronium C_{max} occurred at 6 minutes. Steady state is achieved after approximately 3 days of repeated dosing of BREZTRI AEROSPHERE and the extent of exposure is approximately 1.8 times higher than after the first dose.

Formoterol

Following inhaled administration of BREZTRI AEROSPHERE in subjects with COPD, formoterol C_{max} occurred within 40 to 60 minutes. Steady state is achieved after approximately 2 days of repeated dosing with BREZTRI AEROSPHERE and the extent of exposure is approximately 1.4 times higher than after the first dose.

Distribution:

Budesonide

The estimated budesonide apparent volume of distribution at steady-state is 1200 L, via population pharmacokinetic analysis. Plasma protein binding is approximately 90% for budesonide.

Glycopyrronium

The estimated glycopyrronium apparent volume of distribution at steady-state is 5500 L, via population pharmacokinetic analysis. Over the concentration range of 2-500 nmol/L, plasma protein binding of glycopyrronium ranged from 43% to 54%.

Formoterol

The estimated formoterol apparent volume of distribution at steady-state is 2400 L, via population pharmacokinetic analysis. Over the concentration range of 10-500 nmol/L, plasma protein binding of formoterol ranged from 46% to 58%.

Metabolism:

Budesonide

Budesonide undergoes an extensive degree (approximately 90%) of biotransformation on first passage through the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6 beta-hydroxy-budesonide and 16α -hydroxy-prednisolone, is less than 1% of that of budesonide.

Glycopyrronium

Based on literature, and an *in-vitro* human hepatocyte study, metabolism plays a minor role in the overall elimination of glycopyrronium. CYP2D6 was found to be the predominant enzyme involved in the metabolism of glycopyrronium.

Formoterol

The primary metabolism of formoterol is by direct glucuronidation and by O-demethylation followed by conjugation to inactive metabolites. Secondary metabolic pathways include deformylation and sulfate conjugation. CYP2D6 and CYP2C have been identified as being primarily responsible for O-demethylation.

Elimination:

Budesonide

Budesonide is eliminated via metabolism mainly catalysed by the enzyme CYP3A4. The



metabolites of budesonide are excreted in urine as such or in conjugated form. Only negligible amounts of unchanged budesonide have been detected in the urine. The effective terminal elimination half-life of budesonide derived via population pharmacokinetic analysis was 5 hours.

Glycopyrronium

After IV administration of a 0.2 mg dose of radiolabelled glycopyrronium, 85% of the dose was recovered in urine 48 hours post dose and some of radioactivity was also recovered in bile. The effective terminal elimination half-life of glycopyrronium derived via population pharmacokinetic analysis was 15 hours.

Formoterol

The excretion of formoterol was studied in six healthy subjects following simultaneous administration of radiolabelled formoterol via the oral and IV routes. In that study, 62% of the drug-related radioactivity was excreted in the urine while 24% was eliminated in the feces. The effective terminal elimination half-life of formoterol derived via population pharmacokinetic analysis was 10 hours.

Special Populations and Conditions

Age, Sex, Ethnic Origin and Weight:

A population pharmacokinetic analysis of budesonide was performed based on data collected in a total of 220 subjects with COPD. The pharmacokinetics of budesonide was best described by a three-compartment disposition model with first order absorption. The typical clearance (CL/F) of budesonide was 122 L/h.

A population pharmacokinetic analysis of glycopyrronium was performed based on data collected in a total of 481 subjects with COPD. The pharmacokinetics of glycopyrronium was best described by a two-compartment disposition model with first-order absorption and linear elimination. The typical clearance (CL/F) of glycopyrronium was 166 L/h.

A population pharmacokinetic analysis of formoterol was performed based on data collected in a total of 663 subjects with COPD. The pharmacokinetics of formoterol was best described by a two-compartment disposition model with a first-order rate constant of absorption and linear elimination. The typical clearance (CL/F) of formoterol was 124 L/h.

Dose adjustments are not necessary based on the effect of age, gender or weight on the pharmacokinetic parameters of budesonide, glycopyrronium and formoterol.

There were no major differences in total systemic exposure (AUC) for all compounds among healthy Japanese, Chinese and Western subjects. Insufficient pharmacokinetic data is available for other ethnicities or races.

- **Pediatrics (<18 years of age):** BREZTRI AEROSPHERE has not been evaluated in patients under 18 years of age.
- **Geriatrics** (≥ 65 years of age): Based on available data, no adjustment of the dosage of BREZTRI AEROSPHERE in elderly patients is necessary.

The confirmatory trials of BREZTRI AEROSPHERE for COPD included 343 subjects aged 65 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.



• **Hepatic Insufficiency:** No pharmacokinetic studies have been performed with BREZTRI AEROSPHERE in patients with hepatic impairment.

However, because both budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe hepatic impairment. Glycopyrronium is primarily cleared from the systemic circulation by renal excretion and hepatic impairment would therefore not be expected to effect systemic exposure.

• **Renal Insufficiency:** Studies evaluating the effect of renal impairment on the pharmacokinetics of budesonide, glycopyrronium and formoterol were not conducted.

The effect of renal impairment on the exposure to budesonide, glycopyrronium and formoterol for up to 24 weeks was evaluated in a population pharmacokinetic analysis. Estimated glomerular filtration rate (eGFR) varied from 31-192 mL/min representing a range of moderate to no renal impairment. Simulation of the systemic exposure (AUC $_{0-12}$) in subjects with COPD with moderate renal impairment (eGFR of 45 mL/min) indicates an approximate 68% increase for glycopyrronium compared to subjects with COPD with normal renal function (eGFR of >90 mL/min). Renal function was found not to affect exposure to budesonide or formoterol.

11 STORAGE, STABILITY AND DISPOSAL

Store between 15 to 30°C. Store in a dry place.

BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate dihydrate) should be kept protected inside the sealed foil pouch until the administration period starts. After removal from the foil pouch BREZTRI AEROSPHERE should be used within:

- 6 weeks (56 actuation pack size)
- 3 months (120 actuation pack size).

Keep out of sight and reach of children.

12 SPECIAL HANDLING INSTRUCTIONS

The canister should not be broken, punctured or burnt, even when apparently empty. Do not use or store near heat or open flames. Do not expose to temperatures above 50°C and protect from freezing temperatures. If exposed to freezing temperatures, the inhaler should be equilibrated for 1 hour at room temperature prior to taking a dose.

The actuator should be cleaned weekly.



PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: budesonide

Chemical name:

(22RS)-16α,17α-Propylmethylenedioxypregna-1,4-diene-11β,21-diol-3,20-dione

Molecular formula and molecular mass: C₂₅H₃₄O₆; 430.5 g/mol

Structural formula:

Physicochemical properties: White to off-white powder. Budesonide contains the 22R and 22S epimers in an approximate 53:47 ratio. Melts at 224 – 232°C, with decomposition.

Practically insoluble in water and in heptane, sparingly soluble in ethanol, and freely soluble in chloroform.

Proper name: glycopyrronium bromide

Chemical name:

 $3-[(2-cyclopent(3S^*)-(\pm)-3-\{[(2R^*-(\pm))-2-cyclopentyl-2-hydroxy-2-phenylacetyl]oxy\}-1,1-dimethylpyrrolidinium$

Molecular formula and molecular mass: C₁₉H₂₈BrNO₃; 398.3 g/mol

Structural formula:



Physicochemical properties: White or almost white crystalline powder. Contains 2 chiral centers and is a racemate of the R,S and S,R diastereomers. Melts between 191 – 195°C.

Freely soluble in water, soluble in alcohol, insoluble in chloroform and insoluble in ether.

Proper name: formoterol fumarate dihydrate

Chemical name:

(R*,R*)-(±)-N-{2-hydroxy-5-[1-hydroxy-2-{[1-(4-hydroxyphenyl)-2-propanyl]amino}ethyl]phenyl}formamide (2E)-2-butenedioate (2:1), dihydrate

Molecular formula and molecular mass: $(C_{19}H_{24}N_2O_4)_2 \cdot C_4H_4O_4 \cdot (H_2O)_2$; 840.9 g/mol

Structural formula:

Physicochemical properties: White to off-white or slightly yellow powder. Contains 2 chiral centers and is a racemate of a 1:1 mixture of the R,R and S,S diastereomers. Melts between 138 – 140°C.

Slightly soluble in water, soluble in methanol, slightly soluble in 2-propanol and practically insoluble in acetonitrile.

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

COPD

Table 7 - Summary of patient demographics for clinical trials in COPD

Study #	Study design	Treatment and dosage ¹	Study Subjects ² Mean age (Range) Sex (%)	Primary Efficacy Endpoint
PT010005	A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of BGF MDI Relative to GFF MDI and BFF MDI on	BREZTRI AEROSPHERE (364/16.4/11.6 mcg) twice daily budesonide/glycopyrronium/ formoterol fumarate (BGF MDI) 182/16.4/11.6 mcg, twice daily	BREZTRI AEROSPHERE: 2137 BGF MDI: 2121 GFF MDI: 2120 BFF MDI: 2131 Total: 8509	Rate of moderate or severe COPD exacerbations



Study #	Study design	Treatment and dosage ¹	Study Subjects ² Mean age (Range) Sex (%)	Primary Efficacy Endpoint
	COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD	GFF MDI 16.4/11.6 mcg, twice daily BFF MDI 364/11.6 mcg, twice daily	65 years (40-81 years of age) Male 5081 (59.7%) and Female 3428 (40.3%)	
PT010006	A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of BGF MDI, GFF MDI, and BFF MDI Compared with budesonide/for moterol fumarate dihydrate dry powder for inhalation as an Active Control in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease	BREZTRI AEROSPHERE (364/16.4/11.6 mcg), twice daily GFF MDI 16.4/11.6 mcg, twice daily BFF MDI 364/11.6 mcg, twice daily Open label budesonide/formoterol fumarate dihydrate DPI (400/12 mcg), twice daily	BREZTRI AEROSPHERE: 639 GFF MDI: 625 BFF MDI: 314 Open-label active comparator budesonide/ formoterol fumarate dihydrate DPI: 318 Total: 1896 65.5 years (40- 80 years of age) Male 1350 (71.2%) and Female 546 (28.8%)	FEV ₁ area under the curve from 0-4 hours (FEV ₁ AUC ₀₋₄) and change from baseline in morning predose trough FEV ₁ over 24 weeks

Abbreviations: FEV₁ = forced expiratory volume in 1 second; AUC₀₋₄ = area under the curve from 0-4 hours; BGF = budesonide/glycopyrronium/formoterol fumarate; GFF = glycopyrronium/formoterol fumarate dihydrate; BFF = budesonide and formoterol fumarate dihydrate; MDI = metered dose inhaler; DPI = dry powder for inhalation.

Study demographics and trial design

The efficacy and safety of BREZTRI AEROSPHERE was evaluated in two randomised, multicentre, double-blind, parallel-group trials (PT010005 and PT010006) in patients with moderate to very severe COPD who remained symptomatic (COPD Assessment Test (CAT)

¹ Administered orally as two inhalations of BREZTRI AEROSPHERE; BGF MDI 91/8.2/5.8 mcg, GFF MDI 8.2/5.8 mcg, BFF MDI 182/5.8 mcg, or open label budesonide/formoterol fumarate dihydrate DPI 200/6 mcg, twice daily.

² Modified intent to treat (mITT) population: defined as all subjects randomized and treated with post-randomization data obtained prior to discontinuation from the study drug.



score of 10 or above) while receiving 2 or more inhaled maintenance treatments for COPD for at least 6 weeks prior to screening.

PT010005 was a 52-week trial (N=8,509) that compared BREZTRI AEROSPHERE 364/16.4/11.6 mcg or budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF MDI) 182/16.4/11.6 mcg twice daily with glycopyrronium/formoterol fumarate dihydrate (GFF MDI) 16.4/11.6 mcg, and budesonide/formoterol fumarate dihydrate (BFF MDI) 364/11.6mcg twice daily. Patients had moderate to very severe COPD (post-bronchodilator FEV₁ ≥25% to <65% predicted) with a history of 1 or more moderate or severe COPD exacerbation(s) in the year prior to screening. The mean age was 65 years, with 52% of patients aged 65 or over. During the screening period, the mean post-bronchodilator percent predicted FEV₁ was 43%. The mean CAT score was 19.6. A total of 81% of subjects were on ICS-containing treatments prior to screening. At study entry, the most common COPD medications were ICS + LAMA + LABA (39%), ICS + LABA (31%), and LAMA + LABA (14%).

The primary endpoint was the rate of moderate or severe COPD exacerbations. Exacerbations were defined as worsening of 2 or more major symptoms (dyspnea, sputum volume, and sputum color) or worsening of any 1 major symptom together with any 1 of the following minor symptoms: cough, wheeze, sore throat, colds (nasal discharge and/or nasal congestion), and fever without other cause for at least 2 consecutive days. Exacerbations were considered to be moderate severity if treatment with systemic corticosteroids and/or antibiotics for 3 or more days was required. Exacerbations were considered to be severe if they resulted in hospitalization or death. Secondary efficacy endpoints included: time to first moderate or severe COPD exacerbation, rate of severe COPD exacerbations, rate of moderate or severe COPD exacerbations in subjects with ≥2 moderate or severe COPD exacerbations in the prior year. change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score over 24 weeks, change from baseline in average daily rescue albuterol sulfate use over 24 weeks, Transition Dyspnea Index (TDI) focal score over 24 weeks, change from baseline in Exacerbations of Chronic Pulmonary Disease Tool (EXACT) total score over 52 weeks, and time to death (all cause). Primary endpoints in the pulmonary function test (PFT) sub-study included change from baseline in trough FEV₁ over 24 weeks (BREZTRI AEROSPHERE vs. GFF MDI) and FEV₁ AUC₀₋₄ over 24 weeks (BREZTRI AEROSPHERE vs. BFF MDI).

PT010006 was a 24-week trial (N=1,896) that compared BREZTRI AEROSPHERE 364/16.4/11.6 mcg twice daily, glycopyrronium/formoterol fumarate dihydrate (GFF MDI 16.4/11.6 mcg), budesonide/formoterol fumarate dihydrate (BFF MDI 364/11.6 mcg) and openlabel active comparator budesonide/formoterol fumarate dihydrate dry powder for inhalation (DPI) 400/12 mcg, all administered twice daily.

The two primary endpoints in PT010006 were FEV $_1$ area under the curve from 0-4 hours (FEV $_1$ AUC $_{0-4}$) (BREZTRI AEROSPHERE 364/16.4/11.6 mcg vs. BFF MDI 364/11.6 mcg) and change from baseline in morning pre-dose trough FEV $_1$ over 24 weeks (BREZTRI AEROSPHERE 364/16.4/11.6 mcg vs. GFF MDI 16.4/11.6 mcg). Secondary efficacy endpoints included: change from baseline in morning pre-dose trough FEV $_1$ over 24 weeks (BREZTRI AEROSPHERE 364/16.4/11.6 mcg vs. BFF MDI 364/11.6 mcg), peak change from baseline in FEV $_1$ within 4 hours post dosing over 24 weeks, rate of moderate or severe COPD exacerbations, TDI focal score over 24 weeks, time to CID, change from baseline in SGRQ total score over 24 weeks, change from baseline in average daily rescue Ventolin HFA use over 24 weeks, change from baseline in Evaluating Respiratory Symptoms in COPD total score (RS-Total Score) over 24 weeks, time to onset of action on Day 1.

Trial PT010006 was conducted in patients with moderate to very severe COPD (post-



bronchodilator FEV $_1 \ge 25\%$ to <80% predicted). A prior history of exacerbations in the last 12 months was not required in PT010006 and 74% of patients did not have a history of moderate/severe exacerbations in the prior year. The mean age was 65 years, with 55% of patients aged 65 or over. During the screening period, the mean post-bronchodilator percent predicted FEV $_1$ was 50%. The mean CAT score was 18.3 and a total of 72% of subjects were on ICS-containing treatments prior to screening. At study entry, the most common COPD medication combinations reported were ICS + LAMA + LABA (27%), ICS + LABA (38%), and LAMA + LABA (20%).

Effects on exacerbations - Study PT010005

Rate of moderate or severe exacerbations

BREZTRI AEROSPHERE 364/16.4/11.6 mcg statistically significantly reduced the rate of moderate or severe COPD exacerbations over 52 weeks by 24% and 13% compared with GFF MDI and BFF MDI, respectively (see Table 8).

Rate of severe exacerbations (resulting in hospitalization or death)

BREZTRI AEROSPHERE 364/16.4/11.6 mcg statistically significantly reduced the rate of severe COPD exacerbations over 52 weeks by 20% (HR: 0.80; 95%CI: 0.66, 0.97; p=0.0221) compared with BFF MD.

BREZTRI AEROSPHERE 364/16.4/11.6 mcg numerically reduced the rate of severe COPD exacerbations over 52 weeks by 16% (HR: 0.84; 95%CI: 0.69, 1.03; p=0.0944) compared with GFF MDI.

Benefits on exacerbations were observed in patients with moderate, severe and very severe COPD.

Table 8 - Moderate/Severe COPD Exacerbations, Study PT010005

	BREZTRI AEROSPHERE ¹ 364/16.4/11.6 mcg (N=2137)	GFF MDI ¹ 16.4/11.6 mcg (N=2120)	BFF MDI ¹ 364/11.6 mcg (N=2131)
Rate of moderate or severe exacerbat	ions over 52 weeks		
Rate	1.08	1.42	1.24
Rate Ratio: BREZTRI AEROSPHERE 364/16.4/11.6 mcg vs. comparator		0.76	0.87
% reduction		24%	13%
95% CI		(0.69, 0.83)	(0.79, 0.95)
p-value		p<0.0001	p=0.0027

¹Administered orally as two inhalations of BREZTRI AEROSPHERE 182/8.2/5.8 mcg, GFF MDI 8.2/5.8 mcg, BFF MDI 182/5.8 mcg, twice daily CI= confidence interval

Effects on exacerbations - Study PT010006

BREZTRI AEROSPHERE 364/16.4/11.6 mcg statistically significantly reduced the rate of moderate/severe COPD exacerbations over 24 weeks by 52% (HR: 0.48; 95%CI: 0.37, 0.64;



p<0.0001) compared with GFF MDI. BREZTRI AEROSPHERE 364/16.4/11.6 mcg numerically reduced the rate of moderate/severe COPD exacerbations by 18% compared with BFF MDI.

Effects on lung function – Study PT010005 and Study PT010006

In PT010005 and PT010006, BREZTRI AEROSPHERE provided statistically significant improvements in lung function (FEV₁) compared with GFF MDI and BFF MDI (see Tables 9 and 10 and Figures 1 and 2). The improvements in lung function were sustained over 24 weeks in both studies and over 52-weeks in Study PT010005.

In both studies, there were consistent improvements in lung function in subgroups based on age, sex, degree of airflow limitation (moderate, severe and very severe), and previous inhaled corticosteroid use.

Table 9 – Lung function analyses, Study PT010005


	BREZTRI AEROSPHERE ¹	GFF MDI ¹ 16.4/11.6	BFF MDI ¹ 364/11.6		t difference % Cl	
	364/16.4/11.6 mcg (N=747)	mcg (N=779)	mcg (N=755)	BREZTRI AEROSPHERE vs. GFF MDI	BREZTRI AEROSPHERE vs. BFF MDI	
Trough FEV ₁ (mL) over 24 weeks, LS mean change from baseline (SE)	129 (6.5)	86 (6.6)	53 (6.5)	43 mL (25, 60) p<0.0001*	76 mL (58, 94) p<0.0001	
FEV ₁ AUC ₀₋₄ over 24 weeks; LS mean change from baseline (SE)	294 (6.3)	245 (6.3)	194 (6.3)	49 mL (31, 66) p<0.0001	99 mL (82, 117) p<0.0001*	

¹Administered orally as two inhalations of BREZTRI AEROSPHERE 182/8.2/5.8 mcg, GFF MDI 8.2/5.8 mcg, BFF MDI 182/5.8 mcg, twice daily.

^{*}Statistically significant



Figure 1: Adjusted Mean Change from Baseline in Morning Pre-dose Trough FEV₁ (L) ± SE Over Time – Pulmonary Function Test Sub-study (modified Intent-to-Treat Population)



Abbreviations: FEV₁ = forced expiratory volume in 1 second; GFF = glycopyrronium and formoterol fumarate dihydrate; BFF = budesonide and formoterol fumarate dihydrate; MDI = metered dose inhaler.

¹Administered as two inhalations of BREZTRI AEROSPHERE 182/8.2/5.8 mcg, GFF MDI 8.2/5.8 mcg, BFF MDI 182/5.8 mcg twice daily.

Table 10 - Lung function analyses, Study PT010006


	BREZTRI AEROSPHERE ¹ 364/16.4/11.6 mcg (N=639)	GFF MDI ¹ 16.4/11.6 mcg (N=625)	BFF MDI ¹ 364/11.6 mcg (N=314)	Treatment difference 95% CI	
				BREZTRI AEROSPHERE vs. GFF MDI	BREZTRI AEROSPHERE vs. BFF MDI
Trough FEV ₁ (mL) over 24 weeks, LS mean change from baseline (SE)	147 (6.5)	125 (6.6)	73 (9.2)	22 mL (4, 39) p=0.0139*	74 mL (52, 95) p<0.0001*
FEV ₁ AUC ₀₋₄ over 24 weeks; LS mean change from baseline (SE)	305 (8.4)	288 (8.5)	201 (11.7)	16 mL (-6, 38) p=0.1448	104 mL (77, 131) p<0.0001*

¹Administered orally as two inhalations of BREZTRI AEROSPHERE 182/8.2/5.8 mcg, GFF MDI 8.2/5.8 mcg, BFF MDI 182/5.8 mcg, twice daily.

^{*}Statistically significant



Figure 2: Adjusted Mean Change from Baseline in Morning Pre-dose Trough FEV₁ (L) ± SE Over Time (modified Intent-to-Treat Population)



Abbreviations: FEV₁ = forced expiratory volume in 1 second; GFF = glycopyrronium and formoterol fumarate dihydrate; BFF = budesonide and formoterol fumarate dihydrate; MDI = metered dose inhaler

Effects on symptoms and quality of life

In study PT010005, BREZTRI AEROSPHERE 364/16.4/11.6 mcg showed statistically significant improvements over 24 weeks in breathlessness (assessed by TDI) and statistically significant improvements in disease-specific health status (as assessed by SGRQ) compared to GFF MDI and BFF MDI.

In study PT010006, BREZTRI AEROSPHERE 364/16.4/11.6 mcg showed numerical improvements in breathlessness (assessed by TDI) and numerical improvements in disease-specific health status (as assessed by SGRQ) compared to GFF MDI and BFF MDI.

In study PT010005, a SGRQ responder analysis (responder defined as a reduction in SGRQ versus baseline of greater than or equal to 4) showed that there was a greater percentage of responders over 24 weeks with BREZTRI AEROSPHERE 364/16.4/11.6 mcg (52%) versus GFF MDI (42%) and BFF MDI (45%).

In study PT010006, a SGRQ responder analysis showed that there was a greater percentage of responders over 24 weeks with BREZTRI AEROSPHERE 364/16.4/11.6 mcg (47%) versus GFF MDI (41%) and BFF MDI (40%).

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology

Non-clinical data reveal no specific hazard for humans based on conventional studies of safety

¹ Administered as two inhalations of BREZTRI AEROSPHERE 182/8.2/5.8 mcg, GFF MDI 8.2/5.8 mcg, BFF MDI 182/5.8 mcg.



pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.

The toxicity observed in animal studies with budesonide, glycopyrronium and formoterol was similar, whether they were given in combination or separately. The effects were associated with pharmacological actions or minor adaptive responses commonly observed in inhalation toxicology studies and dose dependent.

No genotoxicity, carcinogenicity or reproductive toxicology studies have been conducted with BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate dihydrate).

BREZTRI AEROSPHERE contains the excipients 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and calcium chloride as part of the spray-dried porous particle technology in the pressurized liquid propellant HFA-134a. The safety of HFA-134a has been fully evaluated in preclinical studies. DSPC and calcium chloride have a long history of safe use in man and are approved excipients worldwide. Furthermore, inhaled toxicology studies carried out with BREZTRI AEROSPHERE have shown no evidence of any toxicity attributable to the excipients.

Carcinogenicity/Mutagenicity

Budesonide: budesonide demonstrated no tumourigenic potential in mice. In rats, an increased incidence of hepatocellular tumours was observed, considered to be a class-effect in rats from long-term exposure to corticosteroids.

Glycopyrronium: no evidence of carcinogenicity was seen in 2-year studies in rats and mice.

Formoterol: a slight increase in the incidence of uterine leiomyomas has been observed in rats and mice treated with formoterol; an effect which is considered to be a class-effect in rodents after long-term exposure to high doses of β_2 -adrenoreceptor agonists.

Reproductive and Developmental Toxicity

Budesonide: in animal reproduction studies, glucocorticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results are not relevant in humans at the recommended doses.

Glycopyrronium: Animal reproduction studies with glycopyrronium have shown reduced rat and rabbit foetal weights, and low body weight gain of rat offspring before weaning, only at very high doses compared to clinical use.

Formoterol: Animal reproduction studies with formoterol have shown a slightly reduced fertility in male rats at high systemic exposure and implantation losses, as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use.

17 SUPPORTING PRODUCT MONOGRAPHS

- 1. Glycopyrronium (as bromide) / Formoterol Fumarate Dihydrate Pressurized Inhalation Aerosol, 8.3 mcg / 5.8 mcg per metered actuation, Control number 252007, Product Monograph, AstraZeneca Canada Inc. (May 31, 2021).
- 2. OXEZE® TURBUHALER® Dry Powder for Oral Inhalation, 6 mcg/dose and 12 mcg/dose, Control number 213703, Product Monograph, AstraZeneca Canada Inc. (April 23, 2018).



3.	3. SYMBICORT® TURBUHALER® Dry Powder for Oral Inhalation, 100 mcg budesonide and 6 mcg formoterol fumarate dihydrate, 200 mcg budesonide and 6 mcg formoterol fumarate dihydrate, 400 mcg budesonide and 12 mcg formoterol fumarate dihydrate, Control number 244507, Product Monograph, AstraZeneca Canada Inc. (February 8, 2021).					



PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

BREZTRI™ AEROSPHERE®

budesonide / glycopyrronium / formoterol fumarate dihydrate pressurized inhalation suspension

Read this carefully before you start taking **BREZTRI™ AEROSPHERE**® and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **BREZTRI AEROSPHERE**.

What is BREZTRI AEROSPHERE used for?

- BREZTRI AEROSPHERE is used in adults for the long-term treatment of a lung disease called chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
- BREZTRI AEROSPHERE is used to make breathing easier and help prevent worsening of COPD symptoms ("flare ups"). You may experience "flare-ups" during which your symptoms become worse. If you have a history of experiencing "flare-ups" BREZTRI AEROSPHERE can help prevent them from developing in the first place.

BREZTRI AEROSPHERE is not meant to treat asthma, or to provide immediate relief of an asthma attack. Use a fast acting 'rescue' inhaler for any sudden asthma attacks. If you do not have a rescue inhaler, ask your doctor to prescribe one for you.

How does BREZTRI AEROSPHERE work?

BREZTRI AEROSPHERE contains 3 medicinal ingredients:

- budesonide is an inhaled corticosteroid (ICS).
- glycopyrronium is a long-acting muscarinic antagonist (LAMA).
- formoterol fumarate dihydrate is a long-acting beta₂ agonist (LABA).

Budesonide belongs to a group of medicines called corticosteroids. It reduces inflammation in the airways of your lungs, which can ease breathing problems, and help prevent "flare-ups" of your COPD. Glycopyrronium and formoterol fumarate dihydrate belong to a group of medicines called bronchodilators. These two medicines work together to help open and relax the muscles of the airways. This allows more air to get in and out of the lungs. This makes it easier for people with COPD to breathe and helps prevent shortness of breath and wheezing. BREZTRI AEROSPHERE is not a cure for COPD, but it can help to control it. Therefore, it is important to continue to take it regularly, even if you feel fine.

What are the ingredients in BREZTRI AEROSPHERE?

Medicinal ingredients: budesonide, glycopyrronium (as bromide), and formoterol fumarate dihydrate

Non-medicinal ingredients: hydrofluoroalkane (HFA-134a), porous particles (comprised of: 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and calcium chloride).

BREZTRI AEROSPHERE comes in the following dosage forms:

Pressurized inhalation suspension in a metered dose inhaler (for oral inhalation): 182 mcg



budesonide / 8.2 mcg glycopyrronium (as bromide) / 5.8 mcg formoterol fumarate dihydrate per actuation.

Do not use BREZTRI AEROSPHERE:

- if you are allergic to budesonide, glycopyrronium, formoterol fumarate dihydrate or any of the other ingredients of BREZTRI AEROSPHERE;
- to treat sudden symptoms of COPD, such as shortness of breath or wheezing. Always have a rescue inhaler with you to treat sudden symptoms ("flare ups"). If you do not have a rescue inhaler, ask your healthcare professional to prescribe one for you;
- to treat asthma.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take BREZTRI AEROSPHERE. Talk about any health conditions or problems you may have, including if you:

- are a smoker. It is important to quit smoking if you use BREZTRI AEROSPHERE, this will help decrease the symptoms of COPD and may increase your lifespan;
- · are using a rescue inhaler on a regular basis;
- have heart problems, such as:
 - heart disease
 - o rapid or irregular heart beat or any problems with how your heart beats
 - o a condition called "QT prolongation"
- · have high blood pressure;
- have eye problems such as increased pressure in the eye, glaucoma, cataracts, blurry vision or other changes in vision;
- have prostate or bladder problems, or any problems passing urine;
- used to take 20 mg or more of prednisone per day;
- have or are at risk for decreased bone mineral content;
- have ever had seizures:
- have problems with your thyroid gland;
- have diabetes:
- have ever had to stop taking another medication for your breathing problems because you
 were allergic to it or it caused problems;
- have been taking other corticosteroids by mouth or by inhalation;
- have any allergies to food or drugs;
- have or have a history of lung infections such as pneumonia;
- · have low levels of potassium in your blood;
- have kidney or liver problems;
- have or have ever had tuberculosis:
- have chronic or untreated infections:
 - bacterial infection
 - viral infection
 - fungal infection (yeast infection or thrush)
 - parasitic infection
 - herpes simplex infection of the eye
- are pregnant or trying to become pregnant. Your healthcare professional will consider the benefit to you and the risk to your unborn baby;
- · are breastfeeding or planning to breastfeed.

Other warnings you should know about:

Do not stop taking BREZTRI AEROSPHERE without talking to your doctor first. If you stop



treatment on your own, your symptoms may worsen. Talk to your doctor right away if:

- there is a change in your symptoms such as more coughing, wheezing, chest tightness or breathlessness;
- you find that you need to use your rescue inhaler more often than usual.

These could be warning signs that your condition may be getting worse.

Paradoxical bronchospasm: if you feel tightness of the chest, coughing, wheezing or breathlessness right after using BREZTRI AEROSPHERE, you may have a serious condition called "paradoxical bronchospasm" (an unexpected closing of your airways). Stop using BREZTRI AEROSPHERE and seek medical help right away.

Monitoring: During treatment with BREZTRI AEROSPHERE, your doctor may monitor:

- your bones and eyes;
- the effects of corticosteroid therapy on your body;
- your blood sugar levels, especially if you have diabetes;
- your blood potassium levels, especially if you already have low levels of potassium.

Eye problems: BREZTRI AEROSPHERE can cause eye disorders such as:

- cataracts: clouding of the lens in the eye, blurry vision, eye pain;
- glaucoma: an increased pressure in your eyes, eye pain, halos around lights or coloured images, red eyes. Untreated, it may lead to permanent vision loss.

If you have any changes in your vision, tell your healthcare professional **right away**. You may need regular eye exams.

Chicken pox and measles: You should avoid exposure to chicken pox and measles, and tell your doctor if you are exposed. This is important if you are taking any cortisone-type medicine and your immune system is not working well (if you have difficulty in fighting an infection).

Eosinophilic granulomatosis with polyangiitis (EGPA): Some people experience a flu-like illness called EGPA when taking an inhaled corticosteroid. Tell your healthcare professional if you have:

- a rash,
- pins and needles or numbness of your arms or legs,
- a severe sinus infection and
- worsening lung or breathing problems.

Driving and using machines: BREZTRI AEROSPHERE can cause headaches, or nausea which may affect your ability to drive and use machines. Use caution when driving and using machines until you know how BREZTRI AEROSPHERE affects you.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with BREZTRI AEROSPHERE:

- medicines called beta-blockers (such as atenolol or propranolol), to treat high blood pressure or other heart problems, or to treat glaucoma (such as timolol);
- ketoconazole or itraconazole, to treat fungal infections;
- ritonavir, nelfinavir or cobicistat, to treat HIV infection;
- oral corticosteroids such as prednisone;



- medicines that lower the amount of potassium in your blood, such as some diuretics ("water pills");
- other long-acting medicines similar to this medicine that are used to treat breathing problems, such as medicines containing tiotropium, ipratropium, aclidinium, umeclidinium or salmeterol, arformoterol, vilanterol, olodaterol or indacaterol;
- medicines which are used to treat heart rhythm problems, such as amiodarone;
- medicines used in the treatment of depression (antidepressants or monoamine oxidase inhibitors):
- medicines called "anticholinergics".

Ask your healthcare professional if you are not sure. The use of BREZTRI AEROSPHERE with these medicines is not recommended.

How to take BREZTRI AEROSPHERE:

- Read the Instructions for Use at the end of this Patient Medication Information for instructions on how to use BREZTRI AEROSPHERE. If you have any questions, talk to your healthcare professional.
- This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- Take BREZTRI AEROSPHERE exactly as your healthcare professional tells you to.
- Take every day as prescribed, even if you have no symptoms of COPD.
- After you take your dose, always rinse your mouth with water and spit it out, do not swallow.

Usual dose:

The recommended dose is 2 oral inhalations (puffs) taken twice daily in the morning and evening.

Overdose:

Signs of an overdosage may include:

- blurred vision;
- dry mouth;
- nausea;
- muscle spasm;
- tremor;
- headache;
- increased heart rate; and
- increased blood pressure.

If you think you, or a person you are caring for, have taken too much BREZTRI AEROSPHERE, contact a healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

Do not take a double dose to make up for a forgotten dose. If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take more than 2 puffs twice a day.



What are possible side effects from using BREZTRI AEROSPHERE?

These are not all the possible side effects you may have when taking BREZTRI AEROSPHERE. If you experience any side effects not listed here, tell your healthcare professional.

- feeling anxious;
- trouble sleeping;
- headache;
- feeling sick (nausea);
- cough and/or a hoarse voice;
- muscle spasms;
- shaking/tremors;
- dry mouth;
- mild irritation in the throat;
- bruising of the skin;
- feeling restless, nervous or agitated;
- feeling dizzy;
- changes in behaviour.

Serious side effects and what to do about them						
2011040 010	Talk to your health	Stop taking drug				
Symptom / effect	Only if severe	In all cases	and get immediate medical help			
COMMON						
Hyperglycemia (high blood sugar): increased thirst, frequent urination, headache, blurred vision and fatigue		√				
Palpitation (fast-beating, fluttering or pounding heart): skipping beats, beating too fast, pounding, fluttering rapidly		✓				
Pneumonia (infection in the lungs): chest pain when you breath or cough, confusion, cough which may produce phlegm, fatigue, fever, sweating and shaking, chills, shortness of breath		√				
Thrush (yeast infection of the mouth or throat): thick white patches in the mouth, tongue or on the throat, sore throat		√				
Urinary tract infection (infection in urinary system including kidneys, ureters, bladder and urethra): pain or burning sensation while urinating, frequent urination,		✓				



Serious side effects and what to do about them						
Symptom / effect	Talk to your healt Only if severe	hcare professional In all cases	Stop taking drug and get immediate medical help			
blood in urine, pain in the pelvis, strong smelling urine, cloudy urine						
UNCOMMON		•				
Allergic Reaction: difficulty swallowing or breathing, wheezing, feeling weak or light headed, feeling sick to your stomach and throwing up, hives or rash, swelling of the face, lips, tongue or throat			✓			
Angina (not enough oxygen to the heart muscle): discomfort in the shoulder, arm, back, throat, jaw or teeth; pain or pressure in the chest		✓				
Arrhythmia (abnormal heart rhythms): rapid, slow or irregular heartbeat		✓				
Bronchospasm (when there is a sudden narrowing of the airway): difficulty breathing with wheezing or coughing			✓			
Depression (sad mood that won't go away): difficulty sleeping or sleeping too much, changes in appetite or weight, feelings of worthlessness, guilt, regret, helplessness or hopelessness, withdrawal from social situations, family, gatherings and activities with friends, reduced sex drive and thoughts of death or suicide. If you have a history of depression, your depression may become worse		✓				
Tachycardia (abnormally fast heartbeat): dizziness, light headedness, shortness of breath, racing heart		✓				
Urinary retention (inability to pass urine or to empty the bladder): painful urination, pain or swelling in the lower abdomen		✓				



Serious side effects and what to do about them						
	Talk to your healthcare professional		Stop taking drug			
Symptom / effect	Only if severe	In all cases	and get immediate medical help			
VERY RARE						
Decreased Adrenal Function:						
tiredness, weakness, nausea	./					
and vomiting, low blood	V					
pressure						
UNKNOWN						
Cataracts: clouding of the lens						
in the eye, blurry vision, dim		✓				
vision and/or eye pain						
Glaucoma: increased pressure						
in your eyes, eye and head pain,						
swelling or redness in or around the eye, changes in vision, hazy		✓				
or blurred vision, sudden sight						
loss						

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting
 (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store between 15 to 30°C. Store in a dry place.

Warning: The canister should not be broken, punctured or burnt, even when it seems empty. Do not use or store near heat or open flames. Do not expose to temperatures higher than 50°C and protect from freezing temperatures. If exposed to freezing temperatures, the inhaler should be equilibrated for 1 hour at room temperature prior to taking a dose.

Use by date: Do not use BREZTRI AEROSPHERE after the expiry date on the label/carton. The expiry date refers to the last day of the month.



After opening the pouch, the inhaler must be used within:

- 6 weeks for an inhaler that contains 56 actuations;
- 3 months for an inhaler than contains 120 actuations.

Dispose of your inhaler after the last dose, following local guidelines. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

Keep out of reach and sight of children.

If you want more information about BREZTRI AEROSPHERE:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer's website www.astrazeneca.ca, or by calling 1-800-668-6000.
- This Patient Medication Information is current at the time of printing. The most up-todate version can be found at www.astrazeneca.ca.

This leaflet was prepared by AstraZeneca Canada Inc. Mississauga, Ontario L4Y 1M4

BREZTRI™ is a trademark of, and AEROSPHERE® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, all used under license by AstraZeneca Canada Inc.

© AstraZeneca 2021

Last Revised: September 30, 2021





INSTRUCTIONS FOR USE

BREZTRI™ AEROSPHERE® budesonide / glycopyrronium / formoterol fumarate dihydrate pressurized inhalation suspension

Read this Instructions for Use before you start using BREZTRI AEROSPHERE and each time you get a new pack. There may be new information. This information does not take the place of talking to your healthcare professional about your medical condition or treatment.

Important Information:

- For oral inhalation use only.
- Use BREZTRI AEROSPHERE exactly as your doctor tells you to.
- If you have any questions about the use of your inhaler, ask your doctor or pharmacist.
- Clean your inhaler once each week. It is very important to keep the plastic actuator clean so that medicine will not build-up and block the spray through the mouthpiece. See Steps 1 through 8 under "How to clean your BREZTRI AEROSPHERE inhaler".

Parts of your BREZTRI AEROSPHERE inhaler (see Figure 1):

- BREZTRI AEROSPHERE comes as a canister that fits into an actuator with a dose indicator.
 - Do not use the BREZTRI AEROSPHERE actuator with a canister of medicine from any other inhaler.
 - Do not use the BREZTRI AEROSPHERE canister with an actuator from any other inhaler.




Figure 1

 BREZTRI AEROSPHERE comes with a dose indicator located on the top of the canister (see Figure 1). The dose indicator display window will show you how many puffs of medicine you have left. A puff of medicine is released each time you press the centre of the dose indicator.



Before you use BREZTRI AEROSPHERE for the first time make sure that the pointer on the dose indicator is pointing to the right of the "120" inhalation mark in the dose indicator display window (**see Figure 1**). (Note: The pointer will point to the right of the "60" inhalation mark if you have a 14-day inhaler, 56 inhalation canister.)

- The pointer will be pointing to 120 after 10 puffs are delivered from BREZTRI AEROSPHERE. This means that there are 120 puffs of medicine left in the canister (see Figure 2a).
- The pointer will be pointing between 100 and 120 after you take 10 more puffs. This means that there are 110 puffs of medicine left in the canister (see Figure 2b).
- The pointer will be pointing to 100 after you take 10 more puffs. This means that there are 100 puffs of medicine left in the canister (see Figure 2c).



Figure 2a 120 puffs



Figure 2b 110 puffs



Figure 2c 100 puffs

• The dose indicator display window will continue to move after every 10 puffs. The number in the dose indicator display window will continue to change after every 20 puffs.



Figure 2d

- The colour in the dose indicator display window will change to red, as shown in the shaded area, when there are only 20 puffs of medicine left in your inhaler (see Figure 2d).
- The dose indicator for the 14-day inhaler, 56 inhalation canister, moves after every 10 puffs; with markings for 60, 40, 20 and 0 puffs. The colour in the 14-day inhaler, 56 inhalation canister dose indicator display window will change to red when there are only 20 puffs of medicine left in your inhaler.

Preparing your BREZTRI AEROSPHERE inhaler for use:

- Your BREZTRI AEROSPHERE inhaler comes in a foil pouch that contains a drying packet (desiccant).
 - o Take the BREZTRI AEROSPHERE inhaler out of the foil pouch.



- Throw away the pouch and the drying packet. Do not eat or breathe in the contents of the drying packet.
- BREZTRI AEROSPHERE should be at room temperature before you use it.
- Store BREZTRI AEROSPHERE in a dry place.




Figure 3

Priming your BREZTRI AEROSPHERE inhaler:

Before you use BREZTRI AEROSPHERE for the first time, you must prime the inhaler.

- Remove the cap from the mouthpiece (see Figure 3). Check inside the mouthpiece for objects before use.
- Hold the inhaler in the upright position away from your face and shake the inhaler well (see Figure 4).




Figure 4

• Press down firmly on the centre of the dose indicator until the canister stops moving in the actuator, to release a puff of medicine from the mouthpiece (see Figure 5). You may hear a soft click from the dose indicator as it counts down during use.






Figure 5

- Repeat the priming steps 3 more times (see Figure 4 and Figure 5). Shake the inhaler well before each priming puff.
- After priming 4 times, the dose indicator should be pointing to the right of "120" and your inhaler is now ready to use.

Using your BREZTRI AEROSPHERE inhaler:

Step 1: Remove the cap from the mouthpiece (see Figure 6).




Figure 6

Step 2: Shake the inhaler well before each use (see Figure 7).




Figure 7



Step 3: Hold the inhaler with the mouthpiece pointing towards you and breathe out as fully as you comfortably can through your mouth (**see Figure 8**).




Figure 8

Step 4: Close your lips around the mouthpiece and tilt your head back, keeping your tongue below the mouthpiece (see Figure 9).




Figure 9

Step 5: While breathing in deeply and slowly, press down on the centre of the dose indicator until the canister stops moving in the actuator and a puff of medicine has been released (**see Figure 10**). Then stop pressing the dose indicator.




Figure 10

Step 6: When you have finished breathing in, remove the mouthpiece from your mouth.



Hold your breath as long as you comfortably can, up to 10 seconds (see Figure 11).




Figure 11

Step 7: Breathe out gently (see Figure 12). Repeat Steps 2 through 7 to take your second puff of BREZTRI AEROSPHERE.




Figure 12

Step 8: Replace the cap over the mouthpiece right away after use (see Figure 13).




Figure 13

Step 9: Rinse your mouth with water to remove any excess medicine. Do not swallow.



How to clean your BREZTRI AEROSPHERE inhaler:

Clean the inhaler once each week. It is very important to keep your inhaler clean so that medicine will not build-up and block the spray through the mouthpiece (see Figure 14).




Figure 14

Step 1: Take the canister out of the actuator (**see Figure 15**). Do not clean the canister or let it get wet.






Figure 15

Step 2: Take the cap off the mouthpiece.

Step 3: Hold the actuator under the tap and run warm water through it for about 30 seconds. Turn the actuator upside down and run warm water through it again for about 30 seconds (see Figure 16).




Figure 16

Step 4: Shake off as much water from the actuator as you can.

Step 5: Look into the actuator and the mouthpiece to make sure any medicine build-up has been completely washed away. If there is any build-up, repeat Steps 3 through 5 in the section "**How to clean your BREZTRI AEROSPHERE inhaler**".

Step 6: Let the actuator air-dry overnight (see Figure 17). Do not put the canister back into the actuator if it is still wet.






Figure 17

Step 7: When the actuator is dry, gently press the canister down in the actuator (**see Figure 18**). Do not press down too hard on the canister. This could cause a puff of medicine to be released.




Figure 18

Step 8: Re-prime your **BREZTRI AEROSPHERE** inhaler after each cleaning. To re-prime the inhaler, shake the inhaler well and press down on the centre of the dose indicator 2 times to release a total of 2 puffs into the air away from your face. Your inhaler is now ready to use.



If you do not use your BREZTRI AEROSPHERE for more than 7 days, or your BREZTRI AEROSPHERE is dropped, you will need to re-prime it before use.

To re-prime the inhaler, shake the inhaler well and press down on the centre of the dose indicator 2 times to release a total of 2 puffs into the air away from your face. Your inhaler is now ready to use.

BREZTRI™ is a trademark of, and AEROSPHERE® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, all used under license by AstraZeneca Canada Inc.

© AstraZeneca 2021

Last Revised: September 30, 2021



INDICATIONS



CONTRAINDICATIONS

DOSAGE & ADMINISTRATION

OVERDOSAGE

DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

WARNINGS & PRECAUTIONS

ADVERSE REACTIONS

DRUG INTERACTIONS

CLINICAL PHARMACOLOGY

STORAGE, STABILITY AND DISPOSAL

SPECIAL HANDLING INSTRUCTIONS

PHARMACEUTICAL INFORMATION

CLINICAL TRIALS

MICROBIOLOGY

NON-CLINICAL TOXICOLOGY

SUPPORTING PRODUCT MONOGRAPHS

PATIENT MEDICATION INFORMATION





